Antibodies MDPI

We have released the first issue of Volume 13! On the cover: "Episomal Vectors for Stable Production of Recombinant Proteins and Engineered Antibodies" by Ian Fallahee and Dr. Daniel Hawiger from Saint Louis University. Read the issue for free at: https://lnkd.in/d6N2AZg5

Results by Dr. Margit Mutso and colleagues at University of Tartu show that three commercial polyclonal antibodies raised against N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) strongly cross-react with endogenous and recombinant mitosis-associated protein Aurora kinase A: https://lnkd.in/gzkjmwiR

In collaboration with the UNICA Cancer Immunotherapy Unit at Hospital 12 de Octubre CNIO - Spanish National Cancer Research Centre, Leadartis scientists headed by Marta Compte Grau, MD, PhD generate and validate a "Trispecific PD-L1 Blocking Antibody that exhibits EGFR-Conditional 4-1BB Agonist Activity". The article has just been published by Antibodies MDPI. Great collaboration with Luis Alvarez-Vallina, MD, Sean Dean Lykke Harwood from Aarhus University and Cristian Smerdou Picazo from CIMA University of Navarra, Universidad ORT Uruguay and Nanogrow Biotech   https://lnkd.in/dXrgmAKi

The #1 #AntibodyEngineering Conference for Accelerating #NextGenerationAntibodies to Commercial Success Register your seat here: https://lnkd.in/e2y52JS4 The Antibody Society

Prof. Ramezani et al. report the expression of aflibercept in a plant-based system with targeted N-glycosylation profiles: https://lnkd.in/dCqfd2W2

In their review, Kahlio Mader and Prof. Lynn B. Dustin from Kennedy Institute of Rheumatology discuss specific examples of non-neutralising antibodies (nNAb) actions in viral infections where they have known importance: https://lnkd.in/eMwPs2GE

Dr. Patrick Koenig and colleagues from 23andMe present the generation and characterization of a common light chain mouse model, in which the endogenous IGKJ cluster is replaced with a prearranged, modified murine IGKV10-96/IGKJ1 segment: https://lnkd.in/dFUS5jC9

🔔 Conference Event: Advance Registration Ends This Friday, 22 March for #IOSummitUK, 23-25 April in London!   With a comprehensive agenda encompassing four distinct yet related programs - Modulating the Tumour Microenvironment, Next Generation Cell-Based Immunotherapies, Bispecific and Multi-specific Antibody Therapeutics and Therapeutic Cancer Vaccines, the Summit promises to be a forum for the exchange of cutting-edge research, and a platform for collaboration among the global immuno-oncology community.   Register today to meet peers, exchange ideas, and find collaborators to accelerate your next IO program. Learn more at https://lnkd.in/dqNuSmZe

🔔 Conference Sharing Advance registration ends this Friday, 22 March for #IOSummitUK! Join us next month to meet peers, exchange ideas, and find collaborators to accelerate your next IO program. Learn more and register today at https://lnkd.in/dtBBQH8E #Immunotherapy #ImmunoOncology MDPI

🔔 New Publication Sharing Episomal Vectors for Stable Production of Recombinant Proteins and Engineered Antibodies by Dr. Daniel Hawiger etc. Daniel Hawiger Saint Louis University School of Medicine Read and download it freely here: https://lnkd.in/gFkjiJDx